Acute bacterial skin and soft tissue infections: new drugs in ID armamentarium
Autor: | Venkatraman Palabindala, Nageshwar Jonnalagadda, Swetha Areti, Sohail Abdul Salim, Raghavendra Tirupathi |
---|---|
Jazyk: | angličtina |
Rok vydání: | 2019 |
Předmět: |
tedizolid
medicine.medical_specialty lcsh:Internal medicine medicine.drug_class Antibiotics MRSA 030204 cardiovascular system & hematology Skin infection 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine delafloxacin Internal medicine Omadacycline Internal Medicine medicine 030212 general & internal medicine cellulitis lcsh:RC31-1245 business.industry Oritavancin Dalbavancin omadacycline medicine.disease chemistry Cellulitis Commentary ceftaroline Tedizolid Delafloxacin business |
Zdroj: | Journal of Community Hospital Internal Medicine Perspectives, Vol 9, Iss 4, Pp 310-313 (2019) Journal of Community Hospital Internal Medicine Perspectives |
ISSN: | 2000-9666 |
Popis: | Acute bacterial skin and soft tissue infections (SSTI) are among the most common reasons for hospitalization of adults in the USA today. Cellulitis or SSTI can cause significant morbidity and mortality. The 2014 IDSA guideline update for the management of skin and soft tissue infections classified skin infections as purulent cellulitis (causative pathogen – Staphylococcus aureus including MRSA) and nonpurulent cellulitis (causative pathogens include Streptococcus). Understanding the key difference and categorization will allow a physician to determine the appropriate treatment approach and antibiotic choice. In recent years, there have been several new antibiotics which received fast track approval by FDA as a Qualified Infectious Disease Product (QIDP) for the indication of SSTI. They Include Ceftaroline (Teflaro), Dalbavancin (Dalvance), Oritavancin (orbativ), Tedizolid (Sevixtro), Delafloxacin (Baxdela) and Omadacycline (Nuzyra). This article will briefly review each of these new antibiotics and summarize their roles in avoiding hospital admissions and reducing the duration of stay in patients with SSTI. |
Databáze: | OpenAIRE |
Externí odkaz: | |
Nepřihlášeným uživatelům se plný text nezobrazuje | K zobrazení výsledku je třeba se přihlásit. |